• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
BEAM

BEAM

Beam Therapeutics Inc.

NASDAQHealthcareBiotechnologyUS
Rating:C

Company Profile

CEO

John Evans

IPO Date

2020-02-06

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

10.0%

Avg Negative

10.7%

Avg Neutral

79.3%

News Feed

Beam Therapeutics: If You Buy Into The Technology, Buy Into The Stock

Seeking Alpha·8/25/2021·↑ positive

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research·8/10/2021·↑ positive

Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results

GlobeNewsWire·8/10/2021·↑ positive

Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Zacks Investment Research·8/4/2021·↑ positive

Beam Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

GlobeNewsWire·8/3/2021·↑ positive

Beam Therapeutics to Participate in the 2021 William Blair Biotech Focus Conference

GlobeNewsWire·7/8/2021·↑ positive

Why Beam Therapeutics Jumped Today

The Motley Fool·6/28/2021·↑ positive

Beam Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare Conference

GlobeNewsWire·5/25/2021·↑ positive

Beam Therapeutics Takes $155M In-Process R&D Expense Hit To Bottomline, But Receives Buy Rating From Redburn Partners

Benzinga·5/11/2021·↓ negative

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research·5/11/2021·↑ positive